Answers are grounded in this paper and cite their sources.
This letter to the editor raises concerns about the certainty of levosimendan's efficacy and safety in treating Takotsubo syndrome.
With interest we read the article by Guo et al . about a study of levosimendan as an adjunctive treatment of 100 patients with Takotsubo syndrome (TTS) (1). The authors concluded that levosimendan “showed reliable efficacy and safety in Chinese elderly patients with TTS, supporting the idea that levosimendan has the potential to be an essential drug applied for patients with TTS” (1). We have the following comments and concerns.
No takes yet. Share an insight, caveat, or question.
Finsterer et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: